Claiming over one million lives each year, viral hepatitis is one of the world’s major public health challenges and disproportionately affects people living in low- and middle-income countries. Therefore access to safe, quality-assured treatments, affordable for all, has to be the fundamental aim of the public health community. This is a big step in that direction [licence agreement on hepatitis C treatment glecaprevir/pibrentasvir
]. The next step is to see more territories included in the agreement. Each step makes the dream of hepatitis C elimination more real.
Raquel Peck, CEO, World Hepatitis Alliance 12 November 2018